NEW YORK, Jan. 29 (GenomeWeb News) - Aclara BioSciences reported decreased revenues, losses, and R&D expenses for the fourth quarter of 2003 yesterday, and said it has won Pfizer as a customer for its eTag assay system.
The company's fourth quarter revenues fell to $653,000 from $752,000 a year ago.
R&D expenses for the quarter decreased to $3.4 million, from $5 million during the same period last year.
Aclara's net losses for the quarter amounted to $3.7 million, or $.10 per share, compared with $7.1 million, or $.20 per share, the year before.
As of Dec. 31, 2003, Aclara had cash and short-term investments of $88.4 million.
Click here for the full earnings report.
Separately, Aclara said that Pfizer will use its eTag assay system at two of its research sites over the next two years.